Scancell Holdings saw a 27% share drop this week as it prepares for a Nasdaq listing through a reverse takeover merger with US company Neuphoria Therapeutics. Scancell shareholders will retain 85.5% ownership in the combined group, gaining access to deeper US biotech markets and funding. The company expects up to $89 million in new funds to advance its lead melanoma treatment into phase III trials, which could justify the current dilution. This move positions Scancell for better valuation and growth opportunities compared to the AIM market in London.
Tompkins Financial Corporation reported strong Q2 2026 results with earnings per share of $2.04, a 36% increase year-over-year, surpassing analyst estimates of $1.82. Quarterly revenue reached $87.12 million, also beating expectations and showing con...
Matador Resources Company, an independent oil and gas producer focused on the Delaware Basin, announced a quarterly cash dividend on July 22, 2026. UBS maintained a "Neutral" rating on the stock but lowered its price target from $62 to $56, implying ...
Morgan Stanley increased its price target for Ryder System to $320, reflecting an 18.27% potential upside based on strong Q2 results. Ryder reported its seventh consecutive quarter of earnings-per-share growth with Q2 EPS of $3.73, beating estimates....
Choice Properties Real Estate Investment Trust reported strong Q2 2026 results, including a 19% average leasing spread and 97.7% portfolio occupancy. The company also saw a 2.8% growth in same-asset net operating income, reflecting solid demand and e...
Tenet Healthcare Corporation reported strong Q2 2026 results, with earnings per share of $6.12, surpassing analyst estimates of $4.26 by a wide margin. Revenue also exceeded expectations at $5.63 billion, showing growth from the previous year. The co...
